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Key Points
• CD30 expression defines
a novel and unique subgroup
of DLBCL with favorable
clinical outcome and distinct
gene expression signature.
CD30, originally identified as a cell-surface marker of Reed-Sternberg and Hodgkin cells
of classical Hodgkin lymphoma, is also expressed by several types of non-Hodgkin
lymphoma, including a subset of diffuse large B-cell lymphoma (DLBCL). However, the
prognostic and biological importance of CD30 expression in DLBCL is unknown. Here
we report that CD30 expression is a favorable prognostic factor in a cohort of 903 de
novo DLBCL patients. CD30 was expressed in ∼14% of DLBCL patients. Patients with
CD301 DLBCL had superior 5-year overall survival (CD301, 79% vs CD30–, 59%; P 5
.001) and progression-free survival (P 5 .003). The favorable outcome of CD30
expression was maintained in both the germinal center B-cell and activated B-cell subtypes. Gene expression profiling revealed the
upregulation of genes encoding negative regulators of nuclear factor kB activation and lymphocyte survival, and downregulation
of genes encoding B-cell receptor signaling and proliferation, as well as prominent cytokine and stromal signatures in CD301
DLBCL patients, suggesting a distinct molecular basis for its favorable outcome. Given the superior prognostic value, unique
gene expression signature, and significant value of CD30 as a therapeutic target for brentuximab vedotin in ongoing successful
clinical trials, it seems appropriate to consider CD301 DLBCL as a distinct subgroup of DLBCL. (Blood. 2013;121(14):2715-2724)
Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common and
one of most heterogeneous types of non-Hodgkin lymphoma. It is
categorized into different morphologic variants, immunohisto-
chemical and molecular subgroups, and distinct subtypes/entities in
the current World Health Organization classiﬁcation.1 According
to gene expression signatures or immunohistochemistry (IHC)
using several algorithms as surrogates, most DLBCL cases can be
placed into prognostically favorable germinal center B-cell–like
(GCB) or prognostically unfavorable activated B-cell–like (ABC)
subtypes.2-9 However, these immunophenotypic algorithms may
not always correlate well with the gene expression proﬁling (GEP)
results and may show poor prognostic power.10-13 Although the
cell of origin (COO) stratiﬁcation by gene expression signatures is
able to provide a general perspective of clinical outcome, currently
it is not practical to perform GEP routinely in the clinical setting.
Furthermore, both subtypes of DLBCL are heterogeneous and
Submitted October 16, 2012; accepted January 11, 2013. Prepublished online
as Blood First Edition paper, January 23, 2013; DOI 10.1182/blood-2012-10-
461848.
The online version of this article contains a data supplement.
There is an Inside Blood commentary on this article in this issue.
The publication costs of this article were defrayed in part by page charge
payment. Therefore, and solely to indicate this fact, this article is hereby
marked “advertisement” in accordance with 18 USC section 1734.
© 2013 by The American Society of Hematology
BLOOD, 4 APRIL 2013 x VOLUME 121, NUMBER 14 2715
For personal use only.on February 13, 2017. by guest  www.bloodjournal.orgFrom 
contain additional subgroups, which have different prognoses and
may require different therapeutic approaches. For example, the
GCB subtype generally carries a favorable prognosis, but it also
includes MYC/BCL2 double-hit B-cell lymphoma, which has an
extremely aggressive clinical course.14,15 Therefore, it is critical to
further stratify cases of DLBCL into biologically similar and clinically
meaningful subgroups, which will not only guide prognostic
assessment and facilitate therapeutic decisions, but also stimulate
further research to understand pathogenesis and develop potential
novel treatments.
CD30, a member of the tumor necrosis factor receptor (TNFR)
superfamily, was originally identiﬁed as a cell-surface marker of
Reed-Sternberg and Hodgkin cells in classical Hodgkin lymphoma.16
CD30 is also expressed by several types of T- and B-cell non-
Hodgkin lymphoma, such as anaplastic large cell lymphoma (ALCL),
primary mediastinal large B-cell lymphoma (PMBCL), and Epstein-
Barr virus (EBV)–driven clonal lymphoproliferative disorders, as
well as in reactive conditions, such as infectious mononucleosis.17
CD30 is an activation marker inducible in vitro by mitogenic
signals and is normally expressed by T and B immunoblasts in
the parafollicular region and the peripheral rim of germinal centers
in healthy individuals. This highly restricted distribution of CD30
expression makes it an ideal target for monoclonal antibody therapy
in patients with CD301 lymphomas. Brentuximab vedotin, an anti-
CD30 monoclonal antibody-drug conjugate recently approved
by the US Food and Drug Administration, has produced marked
responses in relapsed and refractory Hodgkin lymphoma and
systemic ALCL.18-22
Compared with CD30– T-cell or B-cell lymphoma, the favorable
prognoses of ALCL and PMBCL are well established.23-27 However,
the signiﬁcance of CD30 expression in DLBCL, not otherwise spec-
iﬁed (DLBCL-NOS), remains unknown. Early studies in small co-
horts of patients treated with cyclophosphamide, doxorubicin,
vincristine, and prednisone (CHOP) chemotherapy reported in-
consistent results.28,29 The addition of rituximab to the standard
CHOP regimen (R-CHOP) has resulted in improved survival of
patients with DLBCL.30-32 In this study, we assessed CD30 ex-
pression in a large cohort of 903 de novo DLBCL patients who were
treated with R-CHOP immunochemotherapy and correlated CD30
expression with patients’ clinicopathological features, molecular
and genetic changes, gene expression proﬁles, and clinical outcome.
Our results indicate that CD30 expression identiﬁes a novel sub-
group of DLBCL patients with superior clinical outcome.
Materials and methods
Patient selection
We studied 903 cases of de novo DLBCL patients who were treated with
R-CHOP chemotherapy (including 461 cases in the training set and 442 in
the validation set). These cases were organized as a part of the Interna-
tional DLBCL Rituximab-CHOP Consortium Program Study.9,33 All cases
were diagnosed according to the World Health Organization classiﬁcation
criteria and were centrally reviewed by a group of hematopathologists (pri-
mary pathologists, A.T., S.M.M., M.B.M., M.A.P., and K.H.Y.). Cases
were excluded if the patients had a history of low-grade B-cell lymphoma,
acquired immunodeﬁciency, primary cutaneous DLBCL, primary central
nervous system DLBCL, and PMBCL. Cases of EBV1 DLBCL were
analyzed separately from those of EBV– DLBCL given their different clinical
behavior. The study, conducted in accordance with the Declaration of
Helsinki, was reviewed and approved by the Institutional Review Boards of
each participating center, and the comprehensive collaborative study was
approved by the Institutional Review Board at The University of Texas MD
Anderson Cancer Center.9,33
Tissue microarray (TMA) IHC and in situ hybridization for
EBV-encoded RNA
Hematoxylin-eosin stained slides from each of the 903 cases of DLBCL
were reviewed, and TMAs were constructed from tumor cell–rich areas.
IHC studies for a variety of markers using a streptavidin-biotin complex
technique and in situ hybridization for EBV-encoded RNA (EBER)
were performed on 4-mm TMA sections in all cases. The markers assessed
included CD30, CD10, B-cell lymphoma 6 protein (Bcl-6), Germinal Center
B cell-expressed Transcript-1 (GCET1), Multiple Myeloma Oncogene 1
(MUM1), Forkhead box protein P1 (FOXP1), B-cell lymphoma 2 (Bcl-2),
Myc, p53, p21, and Ki-67. Staining was not always achieved for each
marker owing to tissue exhaustion. A cutoff value for each marker was
established from analysis of receiver-operating characteristic curves to
achieve maximum speciﬁcity and sensitivity as described previously.9,33 The
cutoff scores for these markers were as follows: 20% for CD30, 30% for
CD10, 30% for Bcl-6, 60% for GCET1, 60% for MUM1, 60% for FOXP1,
40% for Myc, 70% for Bcl-2, 20% for p53, and 20% for p21. The cutoff
value for Ki-67 was 70%, the median value of Ki-67 for all cases in the
training set.
GEP
Total RNA was extracted from each of the 445 cases in the training set
using the HighPure RNA Extraction Kit (Roche Applied Science,
Indianapolis, IN) and subjected to GEP as previously described.9,33 For
data analysis and classiﬁcation, the microarray DQN signals were generated
and normalized to the quantiles of b distribution. DQN is an ideal expression
algorithm used for expression microarray analysis and represents the non-
central trimmed mean of differences between perfect match and mismatch
intensities with quantile normalization. A Bayesian model was also used to
determine the classiﬁcation probability.34 The methodology developed in this
study has been validated with the Lymphoma Leukemia Molecular Proﬁling
Program dataset in the Gene Expression Omnibus Genomic Spatial Event
database #10846, which has 181 CHOP-treated and 233 R-CHOP–treated
DLBCL patients. We obtained an 80% concordance rate of classiﬁcation for
all 3 classes (GCB, ABC, and unclassiﬁed) and a 97% rate for 2 classes (GCB
and ABC), if excluding the unclassiﬁed. We required a percentage call rate
>12% for the project with a failure rate of 10.64%. The 445 cases with GEP
in this study were part of a larger data set on which proﬁling was successfully
performed and validated.
COO classification
COO classiﬁcation was achieved by combining GEP (considered the “gold
standard”) and IHC data. Brieﬂy, GEP was performed in 445 cases in the
training set, and 442 cases in the validation set. IHC was performed for all
461 cases in the training set and all 442 cases in the validation set. In the
training set, 38 cases not classiﬁable by GEP and 16 additional cases for
which GEP was not performed, as well as all the cases in the validation set
were classiﬁed by IHC methods according to the Visco-Young algorithm.9
The GEP-IHC correlation of COO classiﬁcation was 87.3% in GCB, 86.1%
in ABC, and 86.7% overall.34
Fluorescence in situ hybridization (FISH) for MYC, BCL2,
and BCL6
FISH analysis was performed on formalin-ﬁxed parafﬁn-embedded tissue
sections in each of the 903 cases of DLBCL using BCL2 and BCL6 dual-
color break-apart probes (Vysis, Downers Grove, IL) as described previ-
ously.9 FISH for MYC was performed with a locus-speciﬁc IGH/MYC/
CEP8 tricolor dual-fusion probes and a locus-speciﬁc MYC dual-color
break-apart probe (Vysis). A copy number of threefold to sixfold increase
was considered as low-level ampliﬁcation, and greater than sixfold increase
or tight clusters of at least 5 gene signals as high-level ampliﬁcation.
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Sequencing of TP53
Genomic DNA and total RNA were extracted from formalin-ﬁxed parafﬁn-
embedded tissue samples from each of the 461 cases in the training set.
DNA samples were used for TP53 exon sequencing using p53
AmpliChip (Roche Molecular Systems, Pleasanton, CA).33
Statistical analysis
Clinical and laboratory features at time of presentation between different
DLBCL subgroups were compared using the x2 test and the Spearman rank
correlation. Overall survival (OS) duration was calculated from the date of
diagnosis to the date of last follow-up or death. Progression-free survival
(PFS) duration was calculated from the date of diagnosis to the time of
progression or death. Kaplan-Meier survival curves were used to estimate
OS and PFS rates, and the log-rank (Mantel-Cox) test was used to assess
differences in survival between groups. Multivariate analysis for survival
was performed on IBM statistics SPSS 19 using the Cox proportional haz-
ards regression model. All differences with P < .05 were considered to be
statistically signiﬁcant.
Results
A total of 461 cases of de novo DLBCL patients treated with R-
CHOP were included in the training set for further analysis. These
cases were selected from a data set of 503 cases of de novo DLBCL
in the consortium program after excluding cases of EBV1 DLBCL
(19 cases), cases with unknown CD30 expression status owing to
tissue exhaustion in the TMA (11 cases), patients with a mediastinal
mass regardless of the pathological diagnosis (10 cases), and those
with a cervical mass but for whom a diagnosis of PMBCL was
entertained (2 cases).
Clinical and pathological features
The clinical and pathological features of 461 cases of EBER–
DLBCL in the training set are listed in Table 1. Brieﬂy, there
were 270 men and 191 women (male/female, 1.4:1) with a median
age of 64 years (range, 16-92). Approximately one-third of the
patients presented with B symptoms, and slightly over half (53%)
had advanced Ann Arbor stages. Most of the patients had good
performance status (Eastern Cooperative Oncology Group score 0-
1, 87%), elevated serum lactate dehydrogenase level (61%), and
low or low-intermediate International Prognostic Index (IPI) risk
(IPI score 0-2, 63%). Involvement of multiple extranodal sites
(.2) was seen in 22% of cases, and bulky tumor size .6 cm was
seen in 32% of cases. The vast majority (89%) of the patients
achieved complete or partial remission after R-CHOP therapy. The
median follow-up time was 57 months.
Of the 461 cases, 235 (51%) and 223 (49%) were stratiﬁed as
GCB and ABC subtypes, respectively, by GEP supplemented by
IHC (Table 2). The COO classiﬁcation of 3 cases was not known
because GEP was not done, and IHC studies were not successful
owing to TMA tissue exhaustion.
CD30 expression was associated with favorable prognosis
in DLBCL
Of the 461 cases in the training set, CD30 was positive in 65 cases
(14%), of which 38 were stratiﬁed as GCB, 26 as ABC, and 1 was
unclassiﬁed (Figure 1A-H; Table 2). The training set excluded those
with concurrent CD30 expression and EBV infection, which were
analyzed separately because of apparently different clinical behavior
(Figure 1I-L).
Morphologically, most (56/65, 85%) CD301 DLBCL cases
showed centroblastic features. Eight cases demonstrated pleomorphic
centroblastic/anaplastic morphology. However, it was inherently
difﬁcult to reliably distinguish them. One case showed immunoblastic
features. Most of these cases were diagnosed on the biopsy specimens
of lymph nodes (49/65, 75%), obtained from the abdominal/
retroperitoneal, inguinal, neck (nonsupraclavicular), or axillary re-
gions. The extranodal biopsies of the remaining 16 cases included
those from soft tissue (5); tonsil (2); gastrointestinal tract (2); and
breast, kidney, liver, nasal sinus, orbit, salivary gland, and spleen (1
case each).
After a median follow-up time of 57 months, patients with
CD301 DLBCL showed signiﬁcantly superior OS and PFS com-
pared with those with CD30– DLBCL (Figure 2A-B). The 5-year
OS was 79% in patients with CD301 vs 59% in CD30– DLBCL
(P 5 .0013). The 5-year PFS was 73% in patients with CD301 vs
57% in CD30– DLBCL (P 5 .0030). The favorable prognostic
impact of CD30 expression was validated in an independent cohort
of de novo DLBCL patients treated with R-CHOP and was more
signiﬁcant when combined training and validation sets were ana-
lyzed (Figure 2C-D; supplemental Table 1, see the BloodWeb site).
When the GCB and ABC subtypes were analyzed separately, in
the GCB subtype, patients with CD301 DLBCL had signiﬁcantly
better OS (P5 .0177) and PFS (P5 .0188) than those with CD30–
DLBCL (Figure 3A-B). There was a trend toward better OS (P 5
.0623) and PFS (P 5 .1498) in patients with CD301 DLBCL of
the ABC subtype (Figure 3D-E). The lack of statistical signiﬁcance
in the ABC subtype was apparently due to the lower number of
CD301 cases in this subtype. When combining the training and
validation sets, CD30 expression was a signiﬁcant predictor of
superior survival in both COO subtypes (Figure 3C,F).
Concurrent Myc and Bcl-2 protein expression was previously
shown to be a strong predictor of patient survival in DLBCL.35,36
When all DLBCL cases were stratiﬁed into 2 subgroups with or
without Myc/Bcl-2 coexpression, patients with CD301 DLBCL had
a signiﬁcant better survival than patients with CD30–DLBCL in both
subgroups (supplemental Figure 1). However, CD301 DLBCL with
Myc/Bcl-2 coexpression shows similar survival to CD30– DLBCL
without Myc/Bcl-2 coexpression, consistent with the antagonistic
prognostic impact of CD30 expression and Myc/Bcl-2 double pos-
itivity in DLBCL.
In multivariate analysis, controlling other variables, including B
symptoms, tumor size, IPI risk, COO classiﬁcation, and TP53 mu-
tational status, the lack of CD30 expression remained a signiﬁcant
independent predictor of inferior OS (hazard ratio [HR] of 3.03;
95% conﬁdence interval [CI], 1.33-6.89; P 5 .0082) and PFS (HR
of 2.89; 95% CI, 1.35-6.20; P 5 .0064) (Table 3).
Clinical, pathological, and genetic features of CD301 vs
CD30– DLBCL
Various clinical characteristics were compared between patients
with CD301 and CD30– DLBCL (Table 1). These 2 groups did not
signiﬁcantly differ in any of the clinical parameters examined.
CD301 DLBCL was associated with a trend toward a lower rate of
treatment failure (no response: 5% vs 12%, P5 .0669; no response
and partial response: 15% vs 26%, P 5 .0769).
We then assessed a variety of molecular and genetic factors,
including expression of Bcl-2, Bcl6, Myc, p53, and p21 by IHC;
gene alterations of BCL2, BCL6, and MYC by FISH; and TP53
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mutations by sequencing in the 2 groups (Table 2). Compared with
CD30– DLBCL, CD301 DLBCL showed a lower frequency of
Myc/Bcl-2 coexpression (23% vs 36%, P 5 .0483), a higher fre-
quency of p21 expression (24% vs 11%, P 5 .0034), and no MYC
alterations detected by FISH (rearrangement or ampliﬁcation)
(0% vs 13%, P5 .0100). However, when all cases with Myc/Bcl-2
coexpression, p21 expression, or MYC gene alterations were
excluded from both groups, patients with CD301 DLBCL still
maintained a favorable OS and PFS (supplemental Figure 2). These
results suggest that these 3 factors may not be major factors con-
tributing to the favorable prognosis of patients with CD301 DLBCL.
There was no signiﬁcant difference in the frequency of p53 protein
expression or TP53 gene mutation between the 2 groups (Table 2). A
trend toward a lower frequency of Bcl-2 expression and BCL6
rearrangement or ampliﬁcation, and a lower Ki-67 index were seen
in CD301 DLBCL. However, Bcl-2 expression alone, Ki-67 index,
or BCL6 alterations did not affect patient survival (data not shown).
Gene expression signature of CD301 DLBCL
To identify additional molecular mechanisms underlying the favor-
able prognosis of patients with CD301 DLBCL, we compared the
GEP signatures of CD301 and CD30– DLBCL (Figure 4). A total of
164 independent genes corresponding to 231 array probe sets were
differentially expressed between the 2 groups (P , .001), including
99 genes upregulated and 65 downregulated in CD301DLBCL com-
pared with CD30– DLBCL (supplemental Table 2).
Among the genes with high-level expression in CD301 DLBCL,
9 were cytokines/cytokine receptors and were involved in cytokine
pathways, including IL-1R1, IL-13-Ra1, IL-21R, IL-12B, CCR7,
SOCS1, IRF5, NF1B, and IER2 (Table 4; supplemental Table 2A).
Seven genes encoded TNFR family members, signaling proteins,
or induced proteins. CD30 and FAS induce apoptosis. TRAF1,
Table 1. Clinical characteristics and outcome of 461 cases of de novo DLBCL treated with R-CHOP immunochemotherapy
Overall CD301 CD30–
N (%) OS (P value) PFS (P value) N (%) N (%) P value
Patients 461 (100) 65 (100) 396 (100)
Gender
Male 270 (59) .9688 .6409 38 (58) 232 (59) .9850
Female 191 (41) 27 (42) 164 (41)
Age
#60 188 (41) .0011 .0047 24 (37) 164 (41) .4947
.60 273 (59) 41 (63) 232 (59)
B symptoms*
Absence 276 (69) .0003 .0003 41 (68) 235 (70) .8534
Presence 122 (31) 19 (32) 103 (30)
ECOG performance status*
,2 344 (87) ,.0001 ,.0001 50 (93) 294 (86) .1942
$2 51 (13) 4 (7) 47 (14)
Stage*
I-II 207 (47) ,.0001 ,.0001 34 (53) 173 (46) .2674
III-IV 236 (53) 30 (47) 206 (54)
Extranodal sites*
,2 341 (78) ,.0001 ,.0001 51 (85) 290 (77) .1605
$2 96 (22) 9 (15) 87 (23)
LDH*
Normal 160 (39) .0017 .0002 23 (40) 137 (39) .8775
Elevated 253 (61) 35 (60) 218 (61)
IPI risk group*
0-2 256 (63) ,.0001 ,.0001 40 (73) 216 (61) .1047
3-5 151 (37) 15 (27) 136 (39)
Tumor size (cm)*
,6 222 (68) .0296 .0279 29 (71) 193 (68) .6988
$6 104 (32) 12 (29) 92 (32)
Treatment response
CR/PR 409 (89) ,.0001 ,.0001 62 (95) 347 (88) .0669
No response 52 (11) 3 (5) 49 (12)
CR, complete remission; LDH, lactate dehydrogenase; PR, partial remission; ECOG, eastern cooperative oncology group.
*Clinical information not available in some cases.
Table 2. Pathogenetic characteristics of 461 cases of de novo
DLBCL treated with R-CHOP immunochemotherapy
Overall CD301 CD30– P value
COO classification
GCB 235 (51%) 38 (59%) 197 (50%) .1640
ABC 223 (49%) 26 (41%) 197 (50%)
BCL2 expression 228/454 (50%) 26/65 (40%) 202/389 (52%) .0750
BCL6 expression 369/449 (82%) 51/62 (82%) 318/387 (82%) .9867
MYC expression 295/455 (65%) 38/64 (59%) 257/391 (66%) .3237
MYC/BCL2 coexpression 155/452 (34%) 15/64 (23%) 140/388 (36%) .0483
MYC/BCL6 coexpression 249/445 (56%) 33/64 (52%) 216/381 (57%) .4443
BCL2 aberration 129/395 (33%) 14/59 (24%) 115/336 (34%) .1128
MYC aberration 33/303 (11%) 0/46 (0%) 33/257 (13%) .0100
BCL6 aberration 202/294 (69%) 24/42 (57%) 178/252 (71%) .0808
TP53 mutation 107/461 (23%) 11/65 (17%) 96/396 (24%) .1952
P53 expression 163/449 (36%) 28/62 (45%) 135/387 (35%) .1182
P21 expression 57/449 (13%) 15/62 (24%) 42/387 (11%) .0034
Ki-67 303/454 (67%) 36/64 (56%) 267/390 (68%) .0546
*Cutoff for each of the biomarkers is detailed in the “Materials and methods”
section.
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TNFAIP3, TNFAIP6, TNIP2, and IKBa encode inhibitors of nuclear
factor kB (NF-kB) activation. Fifteen genes were involved in cell-
growth regulation; SLP76/LCP2, LMO2, and CDK6 positively reg-
ulated cell growth, whereas DUSP4, NXN, and SAMSN1 negatively
regulated mitogen-activated protein kinase, Wnt, and B-cell receptor
signaling pathways, respectively. Two HLA genes (HLA-A/F/J and
HLA-DQB1) were also upregulated. Twenty genes encoded various
extracellular matrix proteins, cell adhesion molecules, and molecules
involved in cytoskeletal reorganization.
Among these downregulated genes in CD301 DLBCL, the most
prominent signature was 14 genes involved in B-cell receptor
signaling and proliferation/differentiation, including IGHM, IGL@,
CD72, PKCb, SH2D3C, NFATc1, BACH2, FOXP1, andMIR17HG,
as well as 9 genes involved in cell growth (less lymphocyte speciﬁc),
such as CDCA7L and FZD5 (Wnt receptor) (Table 4; supplemental
Table 2B).
Gene set enrichment analysis (GSEA) reinforced the molecular
association of CD301 DLBCL with the enrichment of genes related
Figure 1. Morphology and immunophenotype of CD301 de novo DLBCL. (A-D) A case of CD301 DLBCL of the GCB subtype (panel A, H&E; panel B, CD30; panel C,
CD10; and panel D, EBER in situ hybridization). (E-H) A case of CD301 DLBCL of the ABC subtype (panel E, H&E; panel F, CD30; panel G, CD10; and panel H, MUM1). (I-L) A
case of CD301EBV1 DLBCL (panel I, H&E; panel J, CD30; panel K, CD10; and panel L, EBER in situ hybridization). Original magnification31000 (A,E,I) and3500 (all others).
Figure 2. Prognostic impact of CD30 expression in
de novo DLBCL. (A-B) OS (A) and PFS (B) of patients
with CD301 vs CD30– DLBCL in the training set. (C) OS
of patients with CD301 vs CD30– DLBCL in the validation
set. These patients were part of an independent cohort of
442 patients with available survival information (supple-
mentary Table 1). (D) OS of patients with CD301 vs
CD30– DLBCL in combined training and validation sets.
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to cytokine and TNFR pathways, cell adhesion molecules,
and B-cell receptor signaling, although the association with
cytokine/TNFR pathways and cell adhesion was more striking
(Figure 4B and data not shown).
We further compared the GEPs of CD301 vs CD30– DLBCL
according to COO subtypes (supplemental Tables 3 and 4). A total
of 52 genes (corresponding to 80 probe sets) were differentially
expressed in GCB CD301DLBCL, and 87 genes (corresponding
to 139 probe sets) in ABC CD301 DLBCL. The majority of these
genes were also present in the GEP of CD301 DLBCL when all
GCB and ABC cases were combined with a few exceptions.
CD40LG and CD80 were upregulated, and IGJ downregulated in
CD301 DLBCL of the GCB subtype (supplemental Table 3).
CD301 DLBCL of the ABC subtype showed increased expression
of additional genes in the cytokine pathway (CXCL13, CCL17,
IL7R, and IRAK2) and decreased expression of BCL2 and CD24
(supplemental Table 4).
CD301EBV1 DLBCL is a unique subset of lymphoma with
aggressive clinical course
Of the total 503 cases in the original data set fromwhich the training
set was derived, 484 were successfully evaluated for EBV infection
by in situ hybridization, and 19 cases (4%) were positive for EBER.
Eight of these 19 cases (42%) were also positive for CD30. Thus,
EBV1 DLBCL more frequently showed CD30 expression than
EBV– DLBCL (42% vs 14%, P5 .0009). Realizing the prognostic
impact of EBV infection in CD301 DLBCL in this data set, 30
additional CD301EBV1 DLBCL cases were included from the
consortium program. Patients with CD301EBV1 DLBCL had
markedly worse OS (P , .0001; Figure 5A) and PFS (P , .0001)
than those with CD301EBER– DLBCL.
Because CD301EBV1 DLBCL cases were associated with ad-
vanced age, we then stratiﬁed patients with CD301EBV1 or CD301
EBV–DLBCL into subgroups according to age (.50 years old,.60
years old, and .70 years old). Compared with CD301EBV–
DLBCL, CD301EBV1 DLBCL had signiﬁcantly poorer survival
in all age subgroups (Figure 5B and data not shown). Given that the
median age of CD301EBV1DLBCLwas 1 to 4 years older than that
of CD301EBV–DLBCL in each age subgroup, we further compared
.50-year-old patients with CD301EBV1 DLBCL vs.60-year-old
patients with CD301EBV– DLBCL because both groups had the
same median ages. Clearly, CD301EBV1 DLBCL showed inferior
Figure 3. Prognostic impact of CD30 expression in
COO subtypes of DLBCL. (A-B) OS (A) and PFS (B)
of patients with CD301 DLBCL of the GCB subtype in
the training set. (C) OS of patients with CD301 DLBCL
of the GCB subtype in the combined training and
validation sets. (D-E) OS (D) and PFS (E) of patients
with CD301 DLBCL of the ABC subtype in the training
set. (F) OS of patients with CD301 DLBCL of the ABC
subtype in the combined training and validation sets.
Table 3. Multivariate analysis of clinicopathological parameters in
de novo DLBCL treated with R-CHOP immunochemotherapy
OS PFS
HR 95% CI P value HR 95% CI P value
B symptoms 1.36 0.95-1.94 .0975 1.38 0.97-1.95 .0712
Tumor size $6 cm 1.16 0.82-1.64 .4154 1.13 0.81-1.58 .4757
IPI score .2 2.83 1.97-4.05 ,.0001 2.59 1.84-3.66 ,.0001
ABC subtype 1.56 1.08-2.24 .0165 1.54 1.08-2.18 .0157
Negative CD30 IHC 3.03 1.33-6.89 .0082 2.89 1.35-6.20 .0064
TP53 mutation 1.96 1.33-2.90 .0007 1.84 1.26-2.69 .0016
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OS (P, .0001; Figure 5C) and PFS (P5 .0001). Furthermore,.60-
year-old patients CD301EBV1 DLBCL had a signiﬁcantly worse
survival than .70-year-old patients with CD301EBV– DLBCL
despite a lower median age in the CD301EBV1 subgroup. These
studies suggest that advanced age is not the major contributing factor
to the dismal survival of patients with CD301EBV1 DLBCL.
Figure 4. Gene expression profiles and GSEA
analysis of CD301 vs CD30– DLBCL. (A) Comparison
of gene expression profiles between CD301 and CD30–
DLBCL. (B) GSEA for differentially expressed genes of
cytokine and TNFR pathways was performed on Kyoto
Encyclopedia of Genes and Genomes pathway gene
sets using all the probe sets that are associated with
a known gene. The gene sets with a false discovery
rate q value ,0.05 after performing 1000 permutations
were considered to be significantly enriched.
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Furthermore, patients with CD301EBV1 DLBCL had inferior
clinical outcome compared with those with CD30–EBER1 DLBCL
despite the favorable prognosis conferred by CD30 expression,
suggesting a synergistic adverse impact between CD30 expression
and EBV infection in this group of patients (data not shown).
Discussion
In this study, we demonstrated that patients with CD301 DLBCL
had superior OS and PFS regardless of COO stratiﬁcation in a
cohort of 903 patients with de novo DLBCL treated with R-CHOP.
CD30 was expressed in ;14% of DLBCL cases. CD301 and
CD30– groups of DLBCL had similar age distributions as well as
many other similar clinicopathological characteristics. It is unlikely
that the observed prognostic difference between these 2 groups is
due to a difference in patient selection.
Unlike Fas or TNFR1, 2 other members of TNFR superfamily,
CD30 does not contain a cytoplasmic death domain. Interestingly,
studies performed in various cell lines showed that activation of CD30
signals cell death or cell-cycle arrest in addition to cell activation.37-39
Multiple in vivo studies in mouse models found that CD30 is required
for lymphocyte apoptosis.40,41 The ﬁndings that expression of
CD30 and CD30 ligand correlates with the regression of lymphoma-
toid papulosis and cutaneous ALCL further support the antiprolifer-
ative role of CD30.42 However, many of these studies were performed
in T cells and Hodgkin lymphoma cells in addition to B cells.
The molecular mechanism of the antiproliferative function of
CD30 is not known. In our GEP studies of CD301 DLBCL, we
observed the upregulation of death receptor FAS and down-
regulation of some oncogenes, such as CDCA7L, FZD5, andDTX1.
Most importantly, multiple genes encoding negative regulators of
the NF-kB pathway and lymphocyte survival were upregulated,
including I-kBa, TNFAIP3, TNFRAIP6, TNIP2, TRAF1, DUSP4,
NXN, SAMSN1, and SOCS1. Furthermore, multiple genes encoding
components of B-cell receptor signaling and proliferation were
downregulated, including IgH m, IgL@, CD72, PKCb, SH2D3C, NF-
ATc1, TCL1A, FOXP1, and BACH2. The inhibition of these
pathways may render lymphoma cells susceptible to chemotherapy-
induced apoptosis.
Interestingly, the GEP of CD301 DLBCL partially overlaps
with that of PMBCL reported by Savage et al43 and Rosenwald
et al. 44 IL-13R, FAS, TRAF1, TNFAIP3, and TNFRAIP6 are
among those upregulated, and IgM, IgL@, PKCb, NF-ATc1, and
FOXP1 among those downregulated in both types of lymphoma.
However, the gene expression signatures of these 2 types of
lymphoma were apparently different. First, they demonstrated
different cytokine proﬁles. Of the total 21 differentially expressed
genes in this functional category (12 genes upregulated in PMBCL
and 9 upregulated in CD301 DLBCL), IL-13Ra1 was the only one
present in both types of lymphoma. Second, several major
histocompatibility complex (MHC) components were downregu-
lated in PMBCL but upregulated in CD301 DLBCL. Loss of MHC
components is associated with poor outcome. Third, although both
showed an incomplete B-cell program, PMBCL appeared to lose
Table 4. Differentially expressed genes in CD301 DLBCL vs CD30– DLBCL
Gene functional categories No. of genes Representative genes
Genes upregulated in CD301 DLBCL
Cytokines and cytokine pathways 9 IL-1R1, IL-12B, IL-13RA1, IL-21R, CCR7,
IRF5, SOCS1, IER2, NFIB
TNFR family and pathways 7 CD30, FAS, TRAF1, NFKBIA, TNFAIP3, TNFAIP6, TNIP2
Cell growth regulation 15 LMO2, SLP76/LCP2, PBX4, DUSP ID2, TUSC1, MIR21, CDK6
MHC class II components 2 HLA-A /F/J, HLA-DQB1
Extracelluar matrix, adhesion, and cytoskeletal organization 20 CDH11, THY1, CD58, CD99, TIAM2
Others, including unknown 46 CHIC2, SOX4, SMARCA2, SUMO3
Genes downregulated in CD301 DLBCL
B-cell receptor signaling and proliferation 14 IGHM, IGL@, PKCB, NF-ATC1, BACH2, TCL1A, FOXP1,
MIR17HG, SH2D3C
Cell growth regulation 9 CDCA7L, FZD5, PTCHD1, BTG2
Extracellular matrix, adhesion, and cytoskeletal organization 7 ST14, SSX2IP, GPR110
Others, including unknown 35 ARF5, GABRB2, XK, ARF5
Figure 5. Prognostic impact of concurrent EBV infection in CD301 DLBCL. (A) OS of all CD301EBER1 vs all CD301EBER– DLBCL patients. Age range, 52 to 91 for
EBV1 group; 16 to 84 for EBV– group. (B) OS of CD301EBER1 vs CD301EBER– DLBCL patients in .60-year-old age group. Median age, 73 for EBV1 group; 70 for EBV–
group. (C) OS of CD301EBV1 DLBCL patients in .50-year-old age group vs CD301EBV– DLBCL in .60-year-old age group. Median age, 70 for both groups.
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more B-cell markers. These markers downregulated in PMBCL but
not in CD301 DLBCL included CD22; cytoplasmic signaling
molecules BLK, SAB, BLNK, and AKT-1; as well as the
transcription factors SPIB and IKAROS. Fourth, multiple costimu-
latory molecules upregulated in PMBCL, such as CD86 and
SLAM, were not upregulated in CD301 DLBCL. Rosenwald et al44
used a 46-gene signature to distinguish PMBCL from de novo
DLBCL, including 35 genes highly expressed in PMBCL and 11
highly expressed in DLBCL. Of these 46 differentially expressed
genes, only 6 were identiﬁed in our CD301 DLBCL GEP studies,
including 5 (CD30, FAS, TRAF1, SAMSN1, and FNBP1)
upregulated and 1 (TCL1A) downregulated in CD301 DLBCL.
These results show that CD301 DLBCL is more related to CD30–
DLBCL than to PMBCL in gene expression signature. Recurrent
genetic alterations in PMBCL, such as CIITA break and STAT6
mutation, are rare in DLBCL.45,46 Despite the distant relatedness
between CD301 DLBCL and PMBCL, it will be interesting to
investigate whether CD301 DLBCL also harbors these genetic
changes.
The ﬁnding of an incomplete B-cell program in CD301 DLBCL
is quite intriguing. In addition to Hodgkin lymphoma and PMBCL,
an incomplete B-cell program is also seen in several other types of
B-cell lymphoma, such as primary effusion lymphoma, plasmablas-
tic lymphoma, some cases of EBV1 DLBCL, and here CD301
DLBCL. All of them are associated with CD30 expression.
Similarly, several types of CD301 peripheral T-cell lymphoma also
show variable loss of the T-cell program, including a subset of
CD301 peripheral T-cell lymphoma NOS, primary cutaneous
CD301 lymphoproliferative disorders, as well as systemic ALCL
(ALK1 and ALK–).47-49 However, it is not clear whether there is
causal relationship between CD30 expression and the loss of B- or
T-cell program.
Regardless, CD30 expression seems to be associated with lym-
phomas with generally favorable outcomes, such as ALCL (vs pe-
ripheral T-cell lymphoma NOS) and PMBCL (vs DLBCL-NOS), and
here, we have demonstrated this trend for CD301DLBCL (vs CD30–
DLBCL). However, CD301EBV1DLBCL had an extremely aggres-
sive clinical course despite the favorable prognostic impact conferred
by CD30 expression. EBV1 DLBCL has been shown to have
prominent NF-kB activation.50 How CD30 synergistically functions
with EBV infection is not known. Further investigation in a larger
cohort of patients is warranted.
Great strides have been made recently in the management of
refractory/relapsed classical Hodgkin lymphoma and ALCL with
the development of the antibody-drug conjugate brentuximab
vedotin. The agent’s dramatic effectiveness andmanageable toxicity
raise the issue of its potential application to other CD301 lympho-
mas, including CD301 DLBCL. In light of the unique gene
expression signature, the prognostic value associated with CD30
expression, and the ongoing successful clinical trials of brentuximab
vedotin in DLBCL, it seems advisable to consider CD301 DLBCL
as a distinct subgroup of DLBCL.
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